# A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

> **NCT05141721** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Project Corporation** · enrollment: 700 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** GRT-C901
- **DRUG:** GRT-R902
- **DRUG:** Atezolizumab
- **DRUG:** Ipilimumab
- **DRUG:** Fluoropyrimidine plus leucovorin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05141721
- **Lead sponsor:** Seattle Project Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-12
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141721, "A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05141721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*